Boehringer Ingelheim
Boehringer Ingelheim and Peking University established a strategic partnership since May 2017 to jointly advance early science innovation across a range of therapeutic areas with high unmet medical needs including cancer, cancer immunology and immune modulation, respiratory, cardiometabolic, central nervous system diseases, etc. This strategic partnership was renewed in 2021 aiming to strengthen Boehringer Ingelheim's portfolio of early and unique pipeline projects supporting the company's aspiration to be at the forefront of science and technology and deliver more first-in-class medicines with breakthrough potential and takes Boehringer Ingelheim's R&D efforts in Asia to the next level.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Boehringer Ingelheim entered Chinese market in 1994, with its headquarters in Shanghai. It operates nationwide and currently has about 3,700 employees across the country. For more information, please visit: www.boehringer-ingelheim.cn, www.boehringer-ingelheim.com